Goldman Sachs Group Inc Arcus Biosciences, Inc. Transaction History
Goldman Sachs Group Inc
- $596 Billion
- Q1 2025
A detailed history of Goldman Sachs Group Inc transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 914,208 shares of RCUS stock, worth $9.35 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
914,208
Previous 914,208
-0.0%
Holding current value
$9.35 Million
Previous $7.18 Million
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding RCUS
# of Institutions
201Shares Held
62.3MCall Options Held
116KPut Options Held
116K-
Black Rock Inc. New York, NY9.76MShares$99.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.69MShares$68.4 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA5.13MShares$52.5 Million0.28% of portfolio
-
State Street Corp Boston, MA3.7MShares$37.8 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.87MShares$29.3 Million0.06% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $738M
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...